Results 11 to 20 of about 24,770 (274)

Percutaneous Coronary Intervention of an Atherosclerotic Right Coronary Artery With Anomalous Origin From the Left Sinus of Valsalva: A Case Report and Literature Review. [PDF]

Clin Case Rep
ABSTRACT Anomalous origin of the right coronary artery from the left sinus of Valsalva can create technical difficulties during angiography and percutaneous coronary intervention. Awareness of this anomaly and use of a systematic, evidence‐based approach are essential to achieve procedural success safely and efficiently.
Gebreselassie MA, Dejene K, Solela G.
europepmc   +2 more sources

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients

Frontiers in Medicine, 2021
Purpose: This study was performed to investigate the effects of common polymorphisms in CYP2D6 and CYP3A5 on the plasma concentrations and antihypertensive effects of bisoprolol in hypertensive Chinese patients.Methods: One hundred patients with ...
Sze Wa Chan, Tanya T. W. Chu, Chung Shun Ho, Alice P. S. Kong, Brian Tomlinson, Brian Tomlinson, Weiwei Zeng   +6 more
doaj   +1 more source

Development and validation of a fast and simple HPLC method for the simultaneous determination of bisoprolol and enalapril in dosage form [PDF]

Pharmacia, 2021
Aim. We aimed to develop and validate fast, simple, accurate, robust and rugged chromatographic method for simultaneous determination of bisoprolol fumarate and enalaril maleate in solid pharmaceutical dosage form, with using chaotropic strong chaotropic
Marjan Piponski, Trajan Balkanov, Liliya Logoyda   +2 more
doaj   +3 more sources

Pharmacogenetic polymorphisms affecting bisoprolol response

Biomedicine & Pharmacotherapy, 2021
β-blockers are commonly prescribed to treat multiple cardiovascular (CV) diseases, but, frequently, adverse drug reactions and intolerance limit their use in clinical practice. Interindividual variability in response to β-blockers may be explained by genetic differences.
Castaño-Amores, Celia, Díaz-Villamarín, Xando, Pérez-Gutiérrez, Ana María, Antúnez-Rodríguez, Alba, Pozo-Agundo, Ana, Moreno-Escobar, Eduardo, Sánchez-Ramos, Jesús Gabriel, Martínez-González, Luis Javier, Dávila-Fajardo, Cristina Lucía   +8 more
openaire   +6 more sources

Pharmacotherapy efficacy and safety criteria based on spectral shifts in elder patients with arterial hypertension and coronary artery disease

Journal of Education, Health and Sport, 2017
The article is dedicated to development of homeostatic criteria of efficacy and safety of drugs combinations “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid”.
V. A. Shtanko, N. V. Tofan, O. V. Khyzhnyak, V. B. Yablonska, S. A. Novikov   +4 more
doaj   +3 more sources

BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME

Рациональная фармакотерапия в кардиологии, 2015
Aim. To compare efficacy of bisoprolol and bisoprolol+metformin combination in patients with arterial hypertension (AH) and metabolic syndrome (MS).Material and methods. 20 patients with AH and MS were involved in the study.
V. A. Nevzorova, N. V. Zakcharchuk, O. V. Nastradin, O. G. Pomogalova   +3 more
doaj   +3 more sources

Bisoprolol transdermal patch treatment for patients with atrial fibrillation after noncardiac surgery: A single-center retrospective study of 61 patients

SAGE Open Medicine, 2020
Objectives: Atrial fibrillation after surgery is associated with increased rates of heart failure and ischemic stroke, and extension of hospitalization. Bisoprolol is a β-blocker used to reduce heart rate and manage arrhythmias during atrial fibrillation.
Taku Yasui, Toru Oka, Wataru Shioyama, Makiko Oboshi, Masashi Fujita   +4 more
doaj   +1 more source

Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension [PDF]

, 2012
Background— In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated. Sympathetic overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run.
Ballegoij, J.J.M. van, Bogaards, S.J.P., Handoko, M.L., Man, F.S. de, Paulus, W.J., Postmus, P.E., Schalij, I., Velden, J. van der, Vonk Noordegraaf, A., Westerhof, N.   +9 more
core   +2 more sources

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol

CPT: Pharmacometrics & Systems Pharmacology, 2021
Merck KGaA observed slight differences in the dissolution of Concor® (bisoprolol) batches over the years. The purpose of this work was to assess the impact of in vitro dissolution on the simulated pharmacokinetics of bisoprolol using in vitro–in vivo ...
Joyce S. Macwan, Grace Fraczkiewicz, Mauro Bertolino, Phillip Krüger, Sheila‐Annie Peters   +4 more
doaj   +1 more source